Jan 10 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant Pharmaceuticals International Inc - Reiterating its full-year 2016 financial guidance, which was originally communicated in november 2016
* FY 2016 earnings per share view $5.43, revenue view $9.60 billion -- Thomson Reuters I/B/E/S Source: Further company coverage: VRX.TO